TW201733599A - 以發炎性疾病為對象之醫藥 - Google Patents

以發炎性疾病為對象之醫藥 Download PDF

Info

Publication number
TW201733599A
TW201733599A TW106105119A TW106105119A TW201733599A TW 201733599 A TW201733599 A TW 201733599A TW 106105119 A TW106105119 A TW 106105119A TW 106105119 A TW106105119 A TW 106105119A TW 201733599 A TW201733599 A TW 201733599A
Authority
TW
Taiwan
Prior art keywords
cells
aforementioned
disease
inflammatory
pharmaceutical composition
Prior art date
Application number
TW106105119A
Other languages
English (en)
Chinese (zh)
Inventor
後藤重則
木村佳司
Original Assignee
醫療法人社團滉志會
邁世耐特股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 醫療法人社團滉志會, 邁世耐特股份有限公司 filed Critical 醫療法人社團滉志會
Publication of TW201733599A publication Critical patent/TW201733599A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW106105119A 2016-02-17 2017-02-16 以發炎性疾病為對象之醫藥 TW201733599A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016028090 2016-02-17

Publications (1)

Publication Number Publication Date
TW201733599A true TW201733599A (zh) 2017-10-01

Family

ID=59625217

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106105119A TW201733599A (zh) 2016-02-17 2017-02-16 以發炎性疾病為對象之醫藥

Country Status (3)

Country Link
JP (1) JPWO2017142014A1 (fr)
TW (1) TW201733599A (fr)
WO (1) WO2017142014A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
JP7374434B2 (ja) * 2018-02-09 2023-11-07 国立大学法人大阪大学 改良されたαβＴ加工細胞製造方法
CA3142355A1 (fr) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations a liberation modifiee et utilisations associees
WO2023072877A1 (fr) * 2021-10-25 2023-05-04 Ellennbe Gmbh Composition pharmaceutique et kit comprenant une substance immuno-modulatrice pour traiter des maladies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311462T3 (es) * 1999-05-05 2009-02-16 University Of Southern California Uso de citocinas y mitogenos para inhibir las respuestas inmunes patologicas.
GB0709803D0 (en) * 2007-05-22 2007-07-04 Ucl Business Plc Predictive method
CA2893962C (fr) * 2012-12-06 2021-04-06 Enlivex Therapeutics Ltd Preparations de cellules apoptotiques therapeutiques, methode de production et utilisations associees

Also Published As

Publication number Publication date
JPWO2017142014A1 (ja) 2018-12-06
WO2017142014A1 (fr) 2017-08-24

Similar Documents

Publication Publication Date Title
Crook et al. Role of myeloid-derived suppressor cells in autoimmune disease
US20150259645A1 (en) Method for inducing il-2-free proliferation of gamma delta t cells
CN101258238B (zh) 抗原呈递细胞的活化处理方法
KR20180041229A (ko) 줄기 세포 이식을 위한 방법
US11464855B2 (en) Antagonism of the VIP signaling pathway
US20170240859A1 (en) Method for producing gamma delta t cells, and pharmaceutical thereof
CN106458869A (zh) 具有免疫疾病治疗效果的新型化合物及其应用
JPWO2017142014A1 (ja) 炎症性疾患を対象とした医薬
WO2013167136A1 (fr) Amélioration de la thérapie cellulaire adoptive avec l'interféron gamma
EP3111945A1 (fr) Produit pharmaceutique contenant des cellules dendritiques, et procédé de production associé
CN111225672B (zh) 甲羟戊酸通路抑制剂及其药物组合物
JPWO2016195086A1 (ja) アレルギー性疾患の治療薬
WO2017064558A1 (fr) Nouveau immunostimulant
CN106668067B (zh) 一种抗肿瘤的联合用药物
CN113454208A (zh) 用于免疫抑制的组合物和方法
JP2010259373A (ja) 抗原提示細胞の活性化処理方法
Hajto The therapeutic application of RBAC in cancer
Auci et al. Synergy of transforming growth factor beta 1 and all trans retinoic acid in the treatment of inflammatory bowel disease: role of regulatory T cells
RU2597414C2 (ru) Способ терапии опухолевых заболеваний
JPWO2008129874A1 (ja) 腫瘍細胞の標的化方法、及びその用途
JP7374434B2 (ja) 改良されたαβＴ加工細胞製造方法
JP2024510403A (ja) 敗血症の新しい治療法
EP4522190A1 (fr) Composition à base de postbiotiques pour le traitement de tumeurs
Sandip Chakraborty et al. Cytotoxic T cells and cancer therapy.
Cuenca et al. Mario Muñoz Builes, María Vela Cuenca, 2 Jose L Fuster Soler, 3 Itziar Astigarraga, 4 Antonia Pascual Martínez, 5 Jose M Vagace Valero, 6 Hoi Y Tong, Jaime Valentín Quiroga, 2 Lucía Fernández Casanova, 7 Adela Escudero López, 8 Luisa Sisinni, 9 Miguel Blanquer, 3 Isabel Mirones Aguilar, 2 Berta González Martínez, 2, 9 Alberto M Borobia, 10 Antonio Pérez-Martínez2, 9